About AVT
Browse Articles
Authors
Customer Services

Current Issue

Displaying 11 results:

Free
Letter

Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir

Edward J Gane, Robert H Hyland, Di An, Evguenia S Svarovskaia, Diana Brainard, John G McHutchison

Antiviral Therapy 2018; 23:284-284


Free
Letter

Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir

Pengcheng Ou, Jun Chen

Antiviral Therapy 2018; 23:283-284


Short communication

Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays

Virginie Mortier, Leen Vancoillie, Kenny Dauwe, Delfien Staelens, Els Demecheleer, Marlies Schauvliege, Sylvie Dinakis, Tom Van Maerken, Géraldine Dessilly, Jean Ruelle, Chris Verhofstede

Antiviral Therapy 2018; 23:277-281


Free
Original article

Drug–drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro

Antje Blank, Katrin Meier, Stephan Urban, Walter Emil Haefeli, Johanna Weiss

Antiviral Therapy 2018; 23:267-275


Original article

Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents

Watsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Torsak Bunupuradah, Tim R Cressey, Angela Colbers, David M Burger, Wanatpreeya Phongsamart, Thanyawee Puthanakit, Chitsanu Pancharoen, HIVNAT 220 study

Antiviral Therapy 2018; 23:259-265


Free
Original article

Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice

Maria Mercedes Santoro, Domenico Di Carlo, Daniele Armenia, Mauro Zaccarelli, Carmela Pinnetti, Manuela Colafigli, Francesca Prati, Andrea Boschi, Anna Maria Degli Antoni, Filippo Lagi, Laura Sighinolfi, Cristina Gervasoni, Massimo Andreoni, Andrea Antinori, Cristina Mussini, Carlo Federico Perno, Vanni Borghi, Gaetana Sterrantino

Antiviral Therapy 2018; 23:249-257


Free
Original article

The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients

Mio Kurihara, Masataka Tsuge, Eisuke Murakami, Nami Mori, Waka Ohishi, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yizhou Zhang, Grace Naswa Makokha, C Nelson Hayes, Kazuaki Chayama

Antiviral Therapy 2018; 23:239-248


Free
Original article

Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir

David Wyles, Alessandra Mangia, Wendy Cheng, Stephen Shafran, Christian Schwabe, Wen Ouyang, Charlotte Hedskog, John McNally, Diana M Brainard, Brian P Doehle, Evguenia Svarovskaia, Michael D Miller, Hongmei Mo, Hadas Dvory-Sobol

Antiviral Therapy 2018; 23:229-238


Free
Original article

Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial

Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim, Baek Gyu Jun, Young Don Kim, Dae Won Jun, Joo Hyun Sohn, Tae Yeob Kim, Byung Seok Lee

Antiviral Therapy 2018; 23:219-227


Free
Original article

Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen

Stéphane Chevaliez, Jordan Feld, Kevin Cheng, Heiner Wedemeyer, Christoph Sarrazin, Benjamin Maasoumy, Christine Herman, John Hackett, Daniel Cohen, George Dawson, Jean-Michel Pawlotsky, Gavin Cloherty

Antiviral Therapy 2018; 23:211-217


Page:
Copyright © Nucleus Global 2018. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.